Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Eli Lilly and (LLY) Stock Price

News stories about Eli Lilly and (NYSE:LLY) have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Eli Lilly and earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.8854878859356 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.02. The firm had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. Eli Lilly and’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.88 earnings per share.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.54%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio is currently 98.58%.

Several equities research analysts have weighed in on LLY shares. UBS AG downgraded Eli Lilly and to a “hold” rating and set a $85.00 price target on the stock. in a report on Wednesday, July 26th. BMO Capital Markets restated a “sell” rating and set a $71.00 price target on shares of Eli Lilly and in a report on Thursday, September 28th. Morgan Stanley set a $86.00 price target on Eli Lilly and and gave the stock a “hold” rating in a report on Friday, October 6th. Piper Jaffray Companies restated a “buy” rating and set a $105.00 price target on shares of Eli Lilly and in a report on Friday, October 13th. Finally, Berenberg Bank restated a “buy” rating and set a $98.00 price target on shares of Eli Lilly and in a report on Friday, August 4th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the stock. Eli Lilly and has an average rating of “Hold” and a consensus price target of $89.76.

TRADEMARK VIOLATION WARNING: This report was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://sportsperspectives.com/2017/11/02/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-eli-lilly-and-lly-stock-price.html.

In related news, major shareholder Lilly Endowment Inc sold 180,000 shares of the business’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00. Following the completion of the sale, the insider now directly owns 123,865,804 shares of the company’s stock, valued at $10,040,562,072.24. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last three months, insiders sold 770,000 shares of company stock valued at $64,669,850. 0.20% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Insider Buying and Selling by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply